BIA-SCC

In September 2022, the FDA announced a second cancer that can develop in the capsule around ANY breast implant, smooth or textured, saline or gel. BIA squamous cell carcinoma (SCC) typically develops approximately 20 years after augmentation, compared to BIA-ALCL which develops approximately 7 to 8 years after augmentation. Unfortunately, BIA-SCC is a more aggressive cancer than BIA-ALCL; fortunately, BIA-SCC is considered very rare, with an estimated incidence of 1 in 164,000. The diagnostic and treatment approaches for BIA-SCC are similar to those for BIA-ALCL.

We remind you that BIA-ALCL was considered very rare in 2016 and now has an incidence of one in 400 with Biocell implants. Time will tell if BIA-SCC is as rare as we assume and hope.